Literature DB >> 19284362

Multitarget drugs: the present and the future of cancer therapy.

Annalisa Petrelli1, Giorgio Valabrega.   

Abstract

Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression -- such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival -- mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284362     DOI: 10.1517/14656560902781907

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  22 in total

1.  Bruceantin inhibits multiple myeloma cancer stem cell proliferation.

Authors:  Mark E Issa; Sarah Berndt; Gilles Carpentier; John M Pezzuto; Muriel Cuendet
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

2.  New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer.

Authors:  Juan Rodrigues; Claudia Abramjuk; Luis Vásquez; Neira Gamboa; José Domínguez; Bianca Nitzsche; Michael Höpfner; Radostina Georgieva; Hans Bäumler; Carsten Stephan; Klaus Jung; Michael Lein; Anja Rabien
Journal:  Pharm Res       Date:  2010-12-24       Impact factor: 4.200

3.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

4.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

5.  Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.

Authors:  Radu O Minea; Corey M Helchowski; Samuel J Zidovetzki; Fritz K Costa; Stephen D Swenson; Francis S Markland
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

6.  Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma.

Authors:  Nu Ry Song; Eunjung Lee; Sanguine Byun; Jong-Eun Kim; Madhusoodanan Mottamal; Jung Han Yoon Park; Soon Sung Lim; Ann M Bode; Hyong Joo Lee; Ki Won Lee; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-08

Review 7.  How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.

Authors:  Mehdi Sanati; Samaneh Aminyavari; Hamid Mollazadeh; Bahram Bibak; Elmira Mohtashami; Amir R Afshari
Journal:  Pharmacol Rep       Date:  2022-01-20       Impact factor: 3.024

8.  Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective.

Authors:  Alan Talevi
Journal:  Front Pharmacol       Date:  2015-09-22       Impact factor: 5.810

9.  miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs.

Authors:  Alessandro Laganà; Mario Acunzo; Giulia Romano; Alfredo Pulvirenti; Dario Veneziano; Luciano Cascione; Rosalba Giugno; Pierluigi Gasparini; Dennis Shasha; Alfredo Ferro; Carlo Maria Croce
Journal:  Nucleic Acids Res       Date:  2014-03-13       Impact factor: 16.971

10.  Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.

Authors:  Raghavendra Gowda; Nathan R Jones; Shubhadeep Banerjee; Gavin P Robertson
Journal:  J Nanomed Nanotechnol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.